Ep 2 | AI for New Drug Design
In the second episode of the series focusing on the use of AI in drug discovery, Nick is joined by the CSO of Iktos. Iktos are an French biotech for ligand-based and structure-based de novo drug design focusing on multi-parametric optimization. The very interesting episode delves into both the technology and also Quentin’s story and how Iktos has become a success story in the biotech space.
Quentin Perron is a medicinal chemist by training. He holds a PhD in organometallic chemistry from the University of Geneva. During his post-doc fellowship at UCLA he worked on the total synthesis of Brasillicardin A, a complex natural molecule known for having a potent immunosuppressive activity. After working as a medicinal chemist in CNS indications at Laboratoires Servier, he switched to data science and chemoinformatics at Quinten, a company specializing in data science services. In 2016, with his business partners Yann Gaston-Mathé and Nicolas Do Huu, he co-founded Iktos, a start-up company developing AI technologies for new drug design. He is now the CSO of the company.